Skip to main content
padlock icon - secure page this page is secure

Recent Patents on Novel P2X7 Receptor Antagonists Potentially Effective for Treatment of Inflammatory Diseases

Buy Article:

$63.00 + tax (Refund Policy)

Involvement of extracellular ATP in inflammatory processes originated in the 1970s when Dahlquist and Diamant reported its histamine releasing action from mast cells. Later a specific ATP receptor was found on these cells, identified as the P2X7 receptor (P2X7R). From these early observations the P2X7R has become increasingly considered as an important regulator of inflammation. Since then, its key role in inflammasome-activated maturation as well as in regulation of the release of several cytokines - including IL-1beta, IL-6, IL-18 and TNF-alpha - has been discovered and widely recognized. Therefore, antagonists of the P2X7 receptor are thought to have therapeutic potential as novel antiinflammatory therapies. The function of the P2X7R in inflammation and its potential role in diseases as well as patent background of its antagonists in the last five years will be reviewed and discussed.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antagonist; Diabetic retinopathy; Mood and anxiety disorders; Neuronal degeneration; Neuronal injury; P2X7 receptor; P2Z receptor; inflammation; inflammatory signaling process; neuropathic pain; patent; therapy

Document Type: Research Article

Publication date: January 1, 2013

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more